Cancer Letters

Cancer Letters

Volume 397, 1 July 2017, Pages 120-126
Cancer Letters

Mini-review
Research progress in advanced melanoma

https://doi.org/10.1016/j.canlet.2017.03.037Get rights and content

Highlights

  • We summarize the most common mutated genes in melanoma.

  • The novel regimens in melanoma treatment are listed in the manuscript and the efficacy of each regimen is compared.

  • Apart from novel regimens, the potential regimens that may benefit melanoma patients are pointed out, such as anti-angiogenesis inhibitors and vaccines.

Abstract

Melanoma is a malignant tumor with high rate of metastasis and poor prognosis. How melanoma develops and how to treat it will continue to be a hot topic. This review briefly summarizes the mechanism of melanoma development and the latest progress in its treatment.

Section snippets

Pathogenesis

How melanoma develops has not been entirely explained. Previous studies identified some risk factors for melanoma development. The main ones are male sex (especially men aged older than 60 years); phenotypic predisposition [1], [2] (people who are sun-sensitive, with red hair and blue eyes, those with atypical moles or a dysplastic nevus pattern etc); medical history and comorbidities [3], [4], [5] (sunburn; precancers such as actinic keratosis; non-melanoma skin cancer such as basal cell and

Progress in treatment

The therapeutic landscape has been rapidly changing in the past decade. Targeted therapy shows better efficacy than traditional chemotherapy. As immune checkpoint agents (e.g., anti-CTLA-4, anti-PD-1) and molecularly-targeted drugs (e.g., BRAF inhibitors, MEK inhibitors) have been included into the treatment of MM, they are gradually taking the place of standard chemotherapy with dacarbazine (DTIC).

In 2017, the National Comprehensive Cancer Network (NCCN) recommendations for patients with

Anti-CTLA-4 inhibitors

CTLA-4 is a member of the immunoglobulin family expressed on the surface of immature cytotoxic T lymphocytes and regulatory T cells. Once the receptor on immature T cell is activated, CTLA-4 competes with CD28 for binding to B7, shutting down the signaling cascade and then inhibiting the immune response. Ipilimumab is a monoclonal antibody against the immune checkpoint receptor CTLA-4. It prevents receptor–ligand interactions, removing the inhibition of T-cell activation and increasing the

BRAF inhibitor monotherapy

Vemurafenib and dabrafenib were developed to inhibit BRAF with mutations at V600 [43], [44], [45]. Results from phase III trials for previously untreated patients with unresectable stage IIIc or stage IV MM, such as BRIM-3 [46], [47] and BREAK-3 [48], [49], showed that monotherapy with either of these agents improved response rates (vemurafenib 48% vs. DTIC 5%, dabrafenib 50% vs. DTIC 5%), PFS (vemurafenib 6.9 months vs. DTIC 1.6 months, dabrafenib 5.1 months vs. DTIC 2.7 months), and OS

Chemotherapy

Common cytotoxic agents used in MM include dacarbazine (DTIC), temozolomide (TMZ), paclitaxel, albumin-bound paclitaxel, and nitrosourea. DTIC monotherapy is still the standard chemotherapy in melanoma treatment. TMZ has a similar mechanism of action as DTIC. A phase III trial showed that DTIC and TMZ were similar with respect to survival time, response rates, and toxicities. However, TMZ showed better efficacy in PFS and quality of life than DTIC [62]. Another study showed that for patients

Biochemotherapy

Biochemotherapy is the combination of chemotherapy and biological agents. Multiple phase II and III trials in patients with metastatic melanoma revealed that biochemotherapy (DTIC or TMZ, cisplatin, and vinblastine or nitrosourea, plus interferon-α [IFN-α] and interleukin-2 [IL-2]) led to overall response rates of 21%–64% and complete response (CR) rates of 7.5%–21% [64], [65], [66], [67]. However, some studies also showed that biochemotherapy had little survival benefit and increased toxicity

High-dose IL-2

High-dose IL-2 has been used extensively in the first-line and second-line settings for advanced melanoma. Though median OS is 11–12 months, approximately 10% patients achieve long-term survival of more than 5 years [70], [71], [72]. A retrospective study that analyzed 305 patients treated with high-dose IL-2 in the second-line setting showed that CR rate was 4% and median duration of response was more than 176 months [70]. However, high-dose IL-2 therapy is associated with significant

Prospects

The incidence of melanoma is rapidly increasing all over the world, with 5-year survival rates of approximately 6% for MM and a median OS of about 6–8 months. In recent years, the therapeutic landscape has rapidly changed with the development of novel agents including BRAF inhibitors, anti-CTLA-4 agents, and anti-PD-1 agents. These new therapies bring hope to patients with MM. However, it's still impractical for most patients because of the high cost and lack of availability in some places.

References (97)

  • G.V. Long et al.

    Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

    Lancet

    (2015)
  • A. Ribas et al.

    Combination of vemurafenib and cobimetinib in patients with advanced BRAF (V600)-mutated melanoma: a phase 1b study

    Lancet Oncol.

    (2014)
  • M. Hecht et al.

    Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients

    Ann. Oncol.

    (2015)
  • S.A. Rosenberg et al.

    Adoptive cell therapy for the treatment of patients with metastatic melanoma

    Curr. Opin. Immunol.

    (2009)
  • C. Cui et al.

    A phase II, randomized, double-blind, placebo-controlled multicenter trial of endostar in patients with metastatic melanoma

    Mol. Ther.

    (2013)
  • R. von Moos et al.

    First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07)

    Ann. Oncol.

    (2012)
  • D.S. Rigel et al.

    Dysplastic nevi. Markers for increased risk for melanoma

    Cancer

    (1989)
  • S.T. Chen et al.

    Update on the epidemiology of melanoma

    Curr. Dermatol. Rep.

    (2013)
  • S. Wu et al.

    Long-term ultraviolet flux, other potential risk factors, and skin cancer risk: a cohort study

    Cancer Epidemiol. Biomarkers Prev.

    (2014)
  • C.M. Olsen et al.

    Increased risk of melanoma in patients with chronic lymphocytic leukaemia: systematic review and meta-analysis of cohort studies

    Melanoma Res.

    (2016)
  • C.M. Olsen et al.

    Risk of melanoma in people with HIV/AIDS in the pre- and post-HAART eras: a systematic review and meta-analysis of cohort studies

    PLoS One

    (2014)
  • A.E. Cust et al.

    Sunbed use during adolescence and early adulthood is associated with increased risk of early-onset melanoma

    Int. J. Cancer

    (2011)
  • T.B. Richards et al.

    Association between cutaneous melanoma incidence rates among white US residents and county-level estimates of solar ultraviolet exposure

    J. Am. Acad. Dermatol.

    (2011)
  • J.A. Jakob et al.

    NRAS mutation status is an independent prognostic factor in metastatic melanoma

    Cancer

    (2012)
  • A.M. Menzies et al.

    Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma

    Clin. Cancer Res.

    (2012)
  • M. Lyle et al.

    Diagnosis and treatment of KIT-mutant metastatic melanoma

    J. Clin. Oncol.

    (2013)
  • C.R. Antonescu et al.

    L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition

    Int. J. Cancer

    (2007)
  • J. Lutzky et al.

    Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation

    Pigment Cell Melanoma Res.

    (2008)
  • M. Vita et al.

    Characterization of S628N: a novel KIT mutation found in a metastatic melanoma

    JAMA Dermatol.

    (2014)
  • E. Laine et al.

    Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanisms

    PLoS Comput. Biol.

    (2011)
  • A. Chaix et al.

    KIT-D816V oncogenic activity is controlled by the juxtamembrane docking site Y568-Y570

    Oncogene

    (2014)
  • G. Monsel et al.

    c-KIT mutants require hypoxia-inducible factor 1 alpha to transform melanocytes

    Oncogene

    (2010)
  • F.C. Kelleher et al.

    Targeting NRAS in melanoma

    Cancer J.

    (2012)
  • I.V. Fedorenko et al.

    NRAS mutant melanoma: biological behavior and future strategies for therapeutic management

    Oncogene

    (2012)
  • A.H. Aguissa-Touré et al.

    Genetic alterations of PTEN in human melanoma

    Cell Mol. Life Sci.

    (2012)
  • R. Abbotts et al.

    Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy

    Oncotarget

    (2014)
  • A.M. Goldstein et al.

    Features associated with geermline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents

    J. Med. Genet.

    (2007)
  • D.T. Bishop et al.

    Geographical variation in the penetrance of CDKN2A mutations for melanoma

    J. Natl. Cancer Inst.

    (2002)
  • L. Vízkeleti et al.

    The role of CCND1 alterations during the progression of cutaneous malignant melanoma

    Tumor Biol.

    (2012)
  • C.D. Van Raamsdonk et al.

    Mutations in GNA11 in uveal melanoma

    N. Engl. J. Med.

    (2010)
  • K.G. Griewank et al.

    TERT Promoter mutation status as an independent prognostic factor in cutaneous melanoma

    J. Natl. Cancer Inst.

    (2014)
  • L.A. Garraway et al.

    Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

    Nature

    (2005)
  • F.S. Hodi et al.

    Improved survival with ipilimumab in patients with metastatic melanoma

    N. Engl. J. Med.

    (2010)
  • C. Robert et al.

    Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

    N. Engl. J. Med.

    (2011)
  • M. Maio et al.

    Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial

    J. Clin. Oncol.

    (2015)
  • C. Robert et al.

    Pembrolizumab versus ipilimumab in advanced melanoma

    N. Engl. J. Med.

    (2015)
  • C. Robert et al.

    Nivolumab in previously untreated melanoma without BRAF mutation

    N. Engl. J. Med.

    (2015)
  • J. Larkin et al.

    Combined nivolumab and ipilimumab or monotherapy in untreated melanoma

    N. Engl. J. Med.

    (2015)
  • Cited by (37)

    • The influence of ultrasound-induced microbubble cavitation on the viability, migration and cell cycle distribution of melanoma cells

      2021, Applied Acoustics
      Citation Excerpt :

      Surgical resection is useful in the early stage of melanoma [1]. When it comes to migration stage, the available treatments are very limited, and the prognosis are poor because of the resistance of melanoma to chemo-, radio-, and immune-therapy [4,7,8]. The way to restrain the migration of malignant melanoma includes drug treatment [9], siRNA transfection [10] and therapy based on signaling pathway [11–13].

    View all citing articles on Scopus
    View full text